On 22 November 2022, the Standing Committee of European Doctors (CPME) has published its position on the revision of the EU general pharmaceutical legislation, urging the EU to restore the balance of the pharmaceutical sector in the interest of patients.
Whereas the publication of a new legislative proposal following the revision was originally planned for Q4 of this year, it is estimated to suffer delays until at least Q2 2023.
The position paper is one of many perspectives and points of concern put forward by key stakeholders at EU level about the shaping of this historical reform - and touches upon some of the trickiest points of discussion, such as resilient supply chains, system of incentives, and market exclusivity. The achievement of the priorities outlined by CPME could highly benefit from the employment of In Silico technologies, whereas the revision envisions fostering the use of artificial intelligence and data analytics for drug discovery and development.
With its position, CPME calls upon the EU to prioritize among others the following aspects within the revision:
The CPME is the European association representing national medical associations across Europe, and is devoted to representing the medical profession’s point of view within EU policy-making.